(Q44905141)

7 December 2017

title

Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation (English)

1 reference

7 December 2017

R R Rosato

1

1 reference

7 December 2017

Y Dai

2

1 reference

7 December 2017

J A Almenara

3

1 reference

7 December 2017

S C Maggio

4

1 reference

7 December 2017

S Grant

5

1 reference

7 December 2017

publication date

1 November 2004

1 reference

7 December 2017

1 reference

7 December 2017

volume

18

1 reference

7 December 2017

issue

11

1 reference

7 December 2017

page(s)

1780-1788

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.leu.2403491

7 December 2017

exact match

0 references

cites work

Identification and characterization of a new member of the TNF family that induces apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403491

The kiss of death: promises and failures of death receptors and ligands in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403491

Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403491

Synergistic induction of apoptosis in human myeloid leukemia cells by phorbol 12-myristate 13-acetate and flavopiridol proceeds via activation of both the intrinsic and tumor necrosis factor-mediated extrinsic cell death pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403491

The histone deacetylase inhibitor sodium butyrate interacts synergistically with phorbol myristate acetate (PMA) to induce mitochondrial damage and apoptosis in human myeloid leukemia cells through a tumor necrosis factor-alpha-mediated process

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403491

Bryostatin 1 and UCN-01 potentiate 1-beta-D-arabinofuranosylcytosine-induced apoptosis in human myeloid leukemia cells through disparate mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403491

The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in human leukemia cells (U937) through the mitochondrial rather than the receptor-mediated pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403491

Flavopiridol induces apoptosis in B-cell chronic lymphocytic leukaemia cells through a p38 and ERK MAP kinase-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403491

Growth inhibition and apoptosis of myeloma cells by the CDK inhibitor flavopiridol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403491

Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403491

Potentiation of 1-beta-D-arabinofuranosylcytosine-mediated mitochondrial damage and apoptosis in human leukemia cells (U937) overexpressing bcl-2 by the kinase inhibitor 7-hydroxystaurosporine (UCN-01).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403491

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403491

Tumor-cell resistance to death receptor--induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403491

TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403491

Butyrate sensitizes human colon cancer cells to TRAIL-mediated apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403491

Death receptors leave a caspase footprint that Smacs of XIAP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403491

Loss of the Bcl-2 phosphorylation loop domain is required to protect human myeloid leukemia cells from flavopiridol-mediated mitochondrial damage and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403491

Mitochondrial control of cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403491

Bcl-2 and apoptosis in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403491

Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403491

Loss of the bcl-2 phosphorylation loop domain increases resistance of human leukemia cells (U937) to paclitaxel-mediated mitochondrial dysfunction and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403491

Bcl-2 and Bcl-xL inhibit CD95-mediated apoptosis by preventing mitochondrial release of Smac/DIABLO and subsequent inactivation of X-linked inhibitor-of-apoptosis protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403491

IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403491

Molecular characterization of mitochondrial apoptosis-inducing factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403491

Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403491

Flavopiridol inhibits P-TEFb and blocks HIV-1 replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403491

Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403491

The IAP family: endogenous caspase inhibitors with multiple biological activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403491

X-linked inhibitor of apoptosis protein (XIAP) is a nonredundant modulator of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403491

Nature's TRAIL--on a path to cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403491

Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403491

Targeting death and decoy receptors of the tumour-necrosis factor superfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403491

XIAP regulates DNA damage-induced apoptosis downstream of caspase-9 cleavage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403491

7 January 2021

Apoptosis and cancer: when BAX is TRAILing away

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403491

7 January 2021

Failure of Bcl-2 to block cytochrome c redistribution during TRAIL-induced apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403491

7 January 2021

Apoptosis-induced by TRAIL AND TNF-alpha in human multiple myeloma cells is not blocked by BCL-2

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403491

7 January 2021

Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403491

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2403491

1 reference

7 December 2017

1 reference